$ARDX Summary of Key Points from the Post Ibsrela (tenapanor for IBS-C):🧐 • TRx (total prescriptions): New record on a 4-week basis.😎 • NRx (new prescriptions): Strongest since the anomalous last two weeks of 2025.💪 • RRx (refill prescriptions): New record.😎 • Total Patients (4-week sum): Still impacted by holiday effects; not yet a record.🤔 • Institutional channel: Accelerated growth noted; however, these shipments are reported monthly, so they are not fully reflected in weekly retail script data yet. He flags this as a reason for caution but also as a source of potential upside. 📈 🔥M-Of_E paints a constructively bullish picture of underlying demand for both products heading into the back half of Q2 2026. 👏🏻👏🏻👏🏻 ✅Record or near-record TRx/RRx/NRx trends, combi
View on X ↗